Apellis Pharmaceuticals Inc (APLS) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.00x

Apellis Pharmaceuticals Inc (APLS) has a Cash Flow Reinvestment Rate of 0.00x as of September 2025, reinvesting $296.00K (capex $148.00K plus investments $-148.00K) from operating cash flow of $108.47 Million. Check APLS cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.00x

(Capex + Investments) / Operating CF

Total Reinvested

$296.00K

Capex + Investments

Operating Cash Flow

$108.47 Million

USD

Capital Expenditures

$148.00K

USD

Apellis Pharmaceuticals Inc Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for Apellis Pharmaceuticals Inc across 1 annual periods. Explore cash flow to debt ratio of Apellis Pharmaceuticals Inc to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Apellis Pharmaceuticals Inc (2025–2025)

Year-by-year capital reinvestment analysis for Apellis Pharmaceuticals Inc. For live market cap and broader valuation context, see Apellis Pharmaceuticals Inc market cap and net worth.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2025	0.01x	$313.00K	$45.33 Million	$313.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow